145 related articles for article (PubMed ID: 37548533)
1. Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy.
Castro DV; Prajapati SR; Feng MI; Chan EH; Lee KO; Paul T; Sehgal I; Patel J; Li X; Zengin ZB; Ebrahimi H; Govindarajan A; Meza L; Mercier BD; Chawla NS; Dizman N; Philip EJ; Hsu J; Bergerot CD; Chehrazi-Raffle A; Rock A; Liu S; Tripathi A; Dorff TB; Pal SK
BJU Int; 2024 Mar; 133(3):297-304. PubMed ID: 37548533
[TBL] [Abstract][Full Text] [Related]
2. Examining Exclusion Criteria in Advanced Prostate Cancer Clinical Trials: An Assessment of recommendations From the American Society Of Clinical Oncology and Friends of Cancer Research.
Ebrahimi H; Castro DV; Feng MI; Prajapati SR; Lee KO; Chan EH; Paul T; Sehgal I; Patel J; Li X; Zengin ZB; Meza L; Mercier BD; Hsu J; Govindarajan A; Chawla N; Dizman N; Bergerot CD; Rock A; Liu S; Tripathi A; Dorff T; Pal SK; Chehrazi-Raffle A
Clin Genitourin Cancer; 2023 Dec; 21(6):e467-e473. PubMed ID: 37301665
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials.
Gan CL; Stukalin I; Meyers DE; Dudani S; Grosjean HAI; Dolter S; Ewanchuk BW; Goutam S; Sander M; Wells C; Pabani A; Cheng T; Monzon J; Morris D; Basappa NS; Pal SK; Wood LA; Donskov F; Choueiri TK; Heng DYC
Eur J Cancer; 2021 Jul; 151():115-125. PubMed ID: 33975059
[TBL] [Abstract][Full Text] [Related]
5. Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement.
Kim ES; Bruinooge SS; Roberts S; Ison G; Lin NU; Gore L; Uldrick TS; Lichtman SM; Roach N; Beaver JA; Sridhara R; Hesketh PJ; Denicoff AM; Garrett-Mayer E; Rubin E; Multani P; Prowell TM; Schenkel C; Kozak M; Allen J; Sigal E; Schilsky RL
J Clin Oncol; 2017 Nov; 35(33):3737-3744. PubMed ID: 28968170
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.
Heng DY; Choueiri TK; Rini BI; Lee J; Yuasa T; Pal SK; Srinivas S; Bjarnason GA; Knox JJ; Mackenzie M; Vaishampayan UN; Tan MH; Rha SY; Donskov F; Agarwal N; Kollmannsberger C; North S; Wood LA
Ann Oncol; 2014 Jan; 25(1):149-54. PubMed ID: 24356626
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection.
Shah NJ; Al-Shbool G; Blackburn M; Cook M; Belouali A; Liu SV; Madhavan S; He AR; Atkins MB; Gibney GT; Kim C
J Immunother Cancer; 2019 Dec; 7(1):353. PubMed ID: 31847881
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices.
Ramsey SD; Unger JM; Baker LH; Little RF; Loomba R; Hwang JP; Chugh R; Konerman MA; Arnold K; Menter AR; Thomas E; Michels RM; Jorgensen CW; Burton GV; Bhadkamkar NA; Hershman DL
JAMA Oncol; 2019 Apr; 5(4):497-505. PubMed ID: 30653226
[TBL] [Abstract][Full Text] [Related]
9. Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients.
Maughan A; Sadigh K; Angulo-Diaz V; Mandimika C; Villanueva M; Lim JK; Ogbuagu O
BMC Infect Dis; 2019 May; 19(1):378. PubMed ID: 31053098
[TBL] [Abstract][Full Text] [Related]
10. Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022.
Xiao H; Vaidya R; Hershman DL; Unger JM
J Clin Oncol; 2024 Jun; 42(16):1953-1960. PubMed ID: 38537158
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials.
Nelson M; Amaya G; Clumeck N; Arns da Cunha C; Jayaweera D; Junod P; Li T; Tebas P; Stevens M; Buelens A; Vanveggel S; Boven K;
J Antimicrob Chemother; 2012 Aug; 67(8):2020-8. PubMed ID: 22532465
[TBL] [Abstract][Full Text] [Related]
12. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group.
Lichtman SM; Harvey RD; Damiette Smit MA; Rahman A; Thompson MA; Roach N; Schenkel C; Bruinooge SS; Cortazar P; Walker D; Fehrenbacher L
J Clin Oncol; 2017 Nov; 35(33):3753-3759. PubMed ID: 28968172
[TBL] [Abstract][Full Text] [Related]
13. Survival benefit with resection of brain metastases from renal cell carcinoma in the setting of molecular targeted therapy and/or immune therapy.
Huntoon K; Damante M; Wang J; Olencki T; Elder JB
Curr Probl Cancer; 2022 Apr; 46(2):100805. PubMed ID: 34836657
[TBL] [Abstract][Full Text] [Related]
14. The Missed Opportunity: HIV, Hepatitis C Virus (HCV), and Hepatitis B Virus (HBV) Positive Patients in Neoadjuvant and Perioperative Immunotherapy Clinical Trials for Lung Cancer.
Benitez Fuentes JD
Cureus; 2023 Dec; 15(12):e51265. PubMed ID: 38161553
[TBL] [Abstract][Full Text] [Related]
15. Antiviral therapy use and related outcomes in patients with cancer and viral infections: results from SWOG S1204.
Hwang JP; Arnold KB; Unger JM; Chugh R; Tincopa MA; Loomba R; Hershman D; Ramsey SD
Support Care Cancer; 2022 Dec; 31(1):93. PubMed ID: 36585488
[TBL] [Abstract][Full Text] [Related]
16. Association between systemic treatment with immune checkpoint inhibitor therapy in renal cell carcinoma and reduced risk of brain metastasis development.
Damante M; Huntoon K; Gibbs D; Pezzutti D; Olencki T; Elder JB
Neurosurg Focus; 2023 Aug; 55(2):E2. PubMed ID: 37527670
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of hepatitis B and C seropositivity in a Nigerian cohort of HIV-infected patients.
Otegbayo JA; Taiwo BO; Akingbola TS; Odaibo GN; Adedapo KS; Penugonda S; Adewole IF; Olaleye DO; Murphy R; Kanki P
Ann Hepatol; 2008; 7(2):152-6. PubMed ID: 18626434
[TBL] [Abstract][Full Text] [Related]
18. Frequency of HCV infection in renal cell carcinoma patients.
Budakoğlu B; Aksoy S; Arslan Ç; Üyetürk Ü; Babacan NA; Özcan MF; Yıldız R; Öven BB; Özdemir NY; Dizdar Ö; Büyükberber S; Akıncı MB; Türker I; Öksüzoğlu B; Altundag K; Zengin N
Med Oncol; 2012 Sep; 29(3):1892-5. PubMed ID: 21461964
[TBL] [Abstract][Full Text] [Related]
19. Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials.
Schwartz LH; Mazumdar M; Wang L; Smith A; Marion S; Panicek DM; Motzer RJ
Cancer; 2003 Oct; 98(8):1611-9. PubMed ID: 14534876
[TBL] [Abstract][Full Text] [Related]
20. Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort.
Ladep NG; Agaba PA; Agbaji O; Muazu A; Ugoagwu P; Imade G; Cooke G; McCormack S; Taylor-Robinson SD; Idoko J; Kanki P
World J Gastroenterol; 2013 Mar; 19(10):1602-10. PubMed ID: 23538773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
